StockData

Nu-Med Plus, Inc. (NUMD) stock

NUMDOTCGold and Silver OresFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 3/30
$0.01−0.00 (-8.16%)

Close on Oct 19, 2026Market cap $601.55KP/E –Yield –

Nu-Med Plus ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Nu-Med Plus's ebitda for the twelve months ending Dec 31, 2022 was -$179.90K. For fiscal 2022 it was -$179.90K. The highest annual figure on record is -$179.90K in fiscal 2022.

Annual ebitda

PeriodPeriod endValueChange
FY2022Dec 31, 2022-$179.90K–
FY2021Dec 31, 2021-$830.08K–
FY2020Dec 31, 2020-$1.98M–
FY2019Dec 31, 2019-$1.01M–
FY2018Dec 31, 2018-$1.15M–
FY2017Dec 31, 2017-$453.98K–
FY2016Dec 31, 2016-$1.22M–
FY2015Dec 31, 2015-$939.33K–
FY2014Dec 31, 2014-$1.14M–
FY2013Dec 31, 2013-$230.44K–
FY2012Dec 31, 2012-$256.41K–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2022Dec 31, 2022-$6.39K–
Q3 FY2022Sep 30, 2022-$58.02K–
Q2 FY2022Jun 30, 2022-$57.85K–
Q1 FY2022Mar 31, 2022-$57.64K–
Q4 FY2021Dec 31, 2021-$109.69K–
Q3 FY2021Sep 30, 2021-$115.72K–
Q2 FY2021Jun 30, 2021-$250.57K–
Q1 FY2021Mar 31, 2021-$354.10K–
Q4 FY2020Dec 31, 2020-$488.51K–
Q3 FY2020Sep 30, 2020-$446.71K–
Q2 FY2020Jun 30, 2020-$901.40K–
Q1 FY2020Mar 31, 2020-$146.27K–
Q4 FY2019Dec 31, 2019-$202.67K–
Q3 FY2019Sep 30, 2019-$143.08K–
Q2 FY2019Jun 30, 2019-$240.36K–
Q1 FY2019Mar 31, 2019-$419.95K–
Q4 FY2018Dec 31, 2018-$332.19K–
Q3 FY2018Sep 30, 2018-$518.49K–
Q2 FY2018Jun 30, 2018-$164.91K–
Q1 FY2018Mar 31, 2018-$138.98K–
Q2 FY2017Jun 30, 2017-$107.72K–
Q1 FY2017Mar 31, 2017-$67.94K–

More Nu-Med Plus figures

See a number that looks wrong?